![]() | |
Names | |
---|---|
IUPAC name
2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C28H31N3O8S | |
Molar mass | 569.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976. [1] It was discovered by Nimbus Therapeutics. [2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease. [3]
![]() | |
Names | |
---|---|
IUPAC name
2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C28H31N3O8S | |
Molar mass | 569.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976. [1] It was discovered by Nimbus Therapeutics. [2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease. [3]